Fig. 1 | Signal Transduction and Targeted Therapy

Fig. 1

From: Knockdown of RNA N6-methyladenosine methyltransferase METTL3 represses Warburg effect in colorectal cancer via regulating HIF-1α

Fig. 1The alternative text for this image may have been generated using AI.

METTL3 and HIF-1α are co-expressed in colorectal cancer (CRC) accompanied with upregulated m6A modification. a The mRNA expression of METTL3 in TCGA-COAD databases. b Total m6A modification level in clinical CRC specimens and paired no-tumor bowel tissues (n = 18). c mRNA expression of METTL3 in each pathological stage of patients in TCGA-COAD databases. d Association of METTL3 and lymph node metastasis (N = no lymph node metastasis, n = 71; Y = lymph node metastasis, n = 39). e Association of METTL3 and distant metastasis (N = no distant metastasis, n = 99; Y = distant metastasis, n = 11). f Association of METTL3 and pathological stage (early stage: stage I and II, n = 68 vs. advanced stage: stages III and IV, n = 42). g Kaplan–Meier analysis showed high expression of METTL3 indicates poor overall survival (p < 0.0001, HR = 4.32, 95% CI = 2.43–7.682). (ns: no significance, *p < 0.05, ***p < 0.001). h Co-expression of METTL3 and HIF-1α in clinical CRC specimens analyzed by Pearson correlation analysis based on H-score (P = 0.000002, R = 0.437, n = 110). i The protein expression of METTL3 and HIF-1α in clinical CRC specimens and paired no-tumor bowel tissues performed by IHC (magnification: ×100 and ×400) (ns: no significance; *p < 0.05, ***p < 0.001)

Back to article page